STOCKS TELEGRAPH

Author: ST Staff

  • What Drove The MRIN Stock Up 10% During Premarket Session?

    What Drove The MRIN Stock Up 10% During Premarket Session?

    Shares of the leading provider of digital marketing software for performance-driven advertisers and agencies, Marin Software Inc (MRIN) were trading up 9.83% in pre-market trading at $10.95 at the time of the last check. During the last session, Martin Software stock decreased -27.07% or -$3.7. Over the course of the session, MRIN shares fluctuated between $9.65 and $12.46. There were 8.2 million shares of MRIN stock exchanged on the day, which is below the company’s 50-day daily volume of 28.23 million and lower than its Year-to-date volume of 11.31 million.

    MRIN stock has gained 527.04% over the past 12 months, but the stock has dropped -43.54% over the last week. For the last six months, MRIN stock has gained a total of 343.11%, and over the last three months, the stock has increased by 507.93%. A total of 393.56% has been earned by the MRIN stock so far this year.  The price of MRN stock rose after the company released its preliminary financial results.

    What quarter did MRN report results?

    Marin Software’s mission is to enable advertisers to run paid marketing programs on the biggest websites in the world more efficiently and transparently. Advertisers and agencies can easily integrate, align, and increases the effectiveness of their digital advertising spend with MRIN’s enterprise marketing software. Search, social, and eCommerce advertising can all be managed through MRN’s single SaaS platform.

    In addition to helping marketers convert audiences more precisely, MRIN is also used to improve financial performance and make better decisions. Globally, MRIN’s technology powers marketing campaigns around the world. The company is headquartered in San Francisco and has offices worldwide.

    As of today, the following preliminary financial results have been announced by Marin Software for the quarter ended June 30, 2021.

    • The second quarter of 2021 is expected to generate MRIN’s net revenues of $6.1 million as opposed to $7.3 million generated in the corresponding quarter of 2020.
    • It is estimated that MRN’s GAAP loss from operations will range from $(3.0) million to $(3.3) million, which is a huge decrease from $(4.5) million for the second quarter 2020.
    • On a non-GAAP basis, the operating losses at MRIN are estimated to range between $(2.8) million and $(3.1) million, considerably less than the $(3.6) million for the second quarter of 2020.
    • At June 30, 2021, MRIN is expected to have, in aggregate, $14.4 million in cash and cash equivalents.
    • According to the information MRIN had available at the time of this release, the preliminary results are estimated.

    These estimated preliminary results of MRIN for the second quarter ended June 30, 2021 may differ from the actual results for the quarter that ends on that date and the final results will not be announced until after that date.

    MRIN’s recent move:

    Marin Software (MRIN) has recently added support for managing Instacart Ads to its flagship platform, MarinOne. By integrating MRIN, brands have an easier time connecting directly with consumers at point of sale. MRIN’s experience helping marketers optimize over $40 billion in digital advertising spend will be brought to the platform’s rapid growth.

  • Do You Know Why FibroGen (FGEN) Stock Dropped 36% In Premarket Trades?

    Do You Know Why FibroGen (FGEN) Stock Dropped 36% In Premarket Trades?

    During Friday’s pre-market trading hours, FibroGen Inc. (FGEN) declined -36.03% to $15.89. The FibroGen stock gained 1.02% to close at $24.84 in last trading session. There was a price range between $24.65 and $25.36 for FGEN stock. The FGEN stock traded 2.15 million shares for the day, exceeding its 100-day average of 1.45 million shares. Shares of FGEN fell -0.84% over the last five days, while they fell -3.80% over the past month. FGEN stock fell after its therapy was recommended to be not approved bya committee at the US Food and Drug Administration (FDA).

    Which FGEN drug is not approved by the FDA?

    FibroGen The aim of FibroGen is to discover, develop, and commercialize new, first-in-class therapeutics. As a leader in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, FGEN develops innovative medicines to treat unmet medical needs. FGEN is currently developing and marketing roxadustat for anemia of chronic kidney disease (CKD), which is an oral small molecule inhibitor of HIF prolyl hydroxylase activity. Additionally, Roxadustat is being tested for anemias associated with myelodysplastic syndromes (MDS) and chemotherapy-induced anemias (CIAs).

    FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has recommended against the approval of roxadustat, according to FibroGen in a press release today.

    • In making its recommendation, the Committee referred to data from more than 8,000 patients in a global Phase 3 program.
    • FDA is not obligated to follow a committee’s vote, but it does consider the Committee’s recommendations when deciding what to approve.
    • Roxadustat is approved to treat anemia of chronic kidney disease in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) adult patients in China, Japan, Chile, and South Korea.
    • This product was also recommended as a positive medicine by the human medicine committee at the Committee for Medicinal Products for Human Use (CHMP) as well as by the EMA’s human medicine committee.
    • The FDA has approved Roxadustat for review for anemia with chronic kidney disease.
    • Treatment for anemia in chronic kidney disease patients could be transformed by Roxadustat .
    • In response to the recommendation, FGEN expressed disappointment.

    FGEN’s strategy going forward:

    Upon Roxadustat’s submission of the New Drug Application, FGEN will work with the scientific evidence to support FDA approval.  Also, FibroGen (FGEN) has appointed John Hunter, Ph.D., Chief Scientific Officer this week. As a global biopharmaceutical leader with more than 20 years of experience, Dr. Hunter will oversee FGEN’s research activities.

  • Phunware Inc. (PHUN) stock surged in the premarket trading session; here’s why

    In the premarket trading session, Phunware Inc. (PHUN stock) jumped up by 5.45% to trade at the price of $1.16 at last check. PHUN stock previously closed the session at a loss of -2.65% at $1.10. The PHUN stock volume traded 1.33 million shares, while in the past 50 days the average daily volume of share has been 2.28 million. In the past year, PHUN shares shed -23.61% and they dropped down in the past week by -13.39%. In the past three and six months, the stock has shed-30.82%, and -9.09% respectively. Furthermore, the PHUN stock is currently valued in the market at $80.08 million and has 64.59 million outstanding shares.

    What you need to know about Phunware Inc.

    Phunware Inc. is a Software-as-a-Service (SaaS) providing company that specifically provides integrated software platform. The company’s business model is b2b where it provides companies products, solutions, management tools and services as well.  The products and services also include cloud-based software which provides licenses in software development kits. The structure used inside versatile applications, for example, analytics that identifies information with application use and commitment; content administration that allows users to make and oversee application content in a cloud-based gateway; cautions, notices, and informing; showcasing mechanization that empowers area set off messages and work process; as well as a platform for promotion.

    There is also on-field based administrations and management that incorporate planning, route, wayfinding, work process, resource the executives, and strategy implementation. The organization likewise connects with the combination of its SDK licenses into existing applications kept up with by its clients, just as custom application improvement and backing administrations; arrangement of cloud-based vertical answers for medical care, retail, sports, avionics, land, accommodation, instruction, and different applications; and offering application exchanges, including re-happening and once value-based media buys for application disclosure, client obtaining and crowd building, crowd commitment, and crowd adaptation.

    Expansion of Phunware’s token and licensing of its Smart Hospitality Solution to a new client

    The company has announced that it has expanded its licensing offering for the Smart Hospitality Solution (SHS) to one of the largest resorts internationally known. Previously the company had a lot of hype and demand for its new digital currency known as PhunToken. It had launched an online portal for its purchasing. PhunToken has a blockchain-engaged Mobile Loyalty Ecosystem to assist with driving responsibility by opening the features and limits of Phunware’s Multiscreen-as-a-Service (“MaaS”) stage. PhunToken is planned to progress advantageous deal compensating purchasers for their movement, like watching marked recordings, completing outlines proposed to grasp purchasing plants and visiting characteristics of interest.

    It comes as no surprise that the hospitality industry is also trying to engage its customers on the online platform, in order to drive demand up post-pandemic. This is why the leading international luxury resort has acquired PHUN stock’s SHS to keep aware of pandemic related safety issues as well as provide tech-enabled experiences.The software will allow its customer to have access to exclusive features like Location based services, Mobile Engagement, Analytics, Content Management and Audience Monetization.

  • Endo International PLC (ENDP) Stock Continues Trending Down as Legal Trials Continue

    Endo International PLC (ENDP) stock prices were down 3.06% as of the market closing on July 15th, 2021, bringing the price per share down to USD$3.49 at the end of the trading day. Subsequent premarket fluctuations have seen the stock dip by 4.01%, bringing it down to USD$3.35.

    Health Canada Approval

    June 9th 2021 saw the company announce the approval of Wakix (pitolisant) by Health Canada for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. The approval of the treatment by Health Canada will facilitate the provision of a much-needed treatment for Canadians that suffer from narcolepsy. The treatment also affords patients the option to manage their EDS or as a treatment for their cataplexy attacks. The company is continuing to offer novel treatment options to help support the unmet needs of the Canadian patient demographic.

    ENDP Partnerships

    The company intends to collaborate with the Canadian Agency for Drugs and Technologies in Health (CADTH), as well as the Institut national d’excellenceensanteen services sociaux (INESSS). This partnership will facilitate the hasty provision of Wakix to its patients. 2018 saw the company’s subsidiary, Endo Ventures Ltd., entered into an agreement with Bioproject SCR. This partnership will see the company register, commercialize and distribute pitolisant on an exclusive basis across Canada. The commercialization of pitolisant in Canada will be conduced by Paladin Labs, an operating company of ENDP.

    Ahead of the Competition

    Wakix is in a class of its own, being the first and only Health Canada approved treatment for EDS and cataplexy symptoms in adult patents with narcolepsy. The first-in-class highly selective histamine 3 receptor antagonist/inverse agonist works through an innovative and unique mechanism of action. It increases the levels of histamine and other wakefulness promoting neurotransmitters in the brain.

    Mechanics of Wakix

    The tablet is to be taken once daily, every morning upon waking up. Wakix is thus far the only treatment for cataplexy that is not a controlled drug, having been approved by Health Canada. The treatment is currently marketed across Europe and the United States, serving as a registered trademark of Bioproject Europe Ltd.

    Future Outlook for ENDP

    Armed with the massively successful scope of the commercialization of Wakix having proliferated the entirety of the North American market, ENDP is poised to capitalize on the expanded opportunities for growth. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Why Does The GLG Stock Rise Premarket?

    Why Does The GLG Stock Rise Premarket?

    Shares of commodities trading service provider in China, TD Holdings Inc. (GLG) gained 18.98% to trade at $0.966 in premarket trading at the time of writing. In Thursday’s session, TD Holdings shares gained 0.12 percent to close at $0.81. Within the past 50 days, GLG stock volume has remained at 0.12 million shares, which is lower than volume of 0.81 million shares traded on the day.

    In the last week, GLG shares have declined by -2.88%, dropping by -69.59% over the last 12 months. GLG shares have dropped by 42.82% over the past three months, while they have dropped by 58.58% over the previous six months. GLG is currently valued at $73.74 million and its outstanding shares were 93.21 million. GLG stock rose after the company signed letters of intent (LOIs) to acquire two companies.

    What is GLG acquiring?

    As a provider of commodities trading and supply chain services, TD Holdings operates in China. In its commodities business, GLG buys non-ferrous metal products from upstream suppliers of metals and minerals and sells them to downstream customers. As a supply chain service business, GLG serves primarily as a one-stop resource for commodity trading, warehouse logistics, information, and digital intelligence in upstream and downstream markets.

    TD TD Holdings has entered into a non-binding LOI with Guangdong Jinbochuang Special Purpose Vehicle Co., Ltd. (“Jinbochuang”) and Hunan Jinmeike New Material Co., Ltd. (“Jinmeike”) and their shareholders, announced the company in a press release today.

    • GLG has signed LOI to purchase both Jinbochuang and Jinmeike for entering the unmanned logistics and new energy vehicle industries.
    • According to the agreement, GLG will acquire 100% of the ownership interest in Jinbochuang and Jinmeike in exchange for its common stock.
    • As a result of the due diligence required by the Company and the parties’ negotiation, the Company determines how many GLG shares to exchange for the acquisition.
    • Assuming satisfactory due diligence and a definitive agreement can be reached, GLG management expects to complete the acquisition within 180 days after signing the LOI.
    • Each participant has the option of unilaterally terminating the LOI.
    • The GLG will disclose necessary information either through SEC filings or press releases as the transaction proceeds.
    • A definitive share exchange agreement needs to be negotiated and executed, along with satisfaction of all conditions negotiated in it, before the deal can close.
    • Among the formalities necessary for the transaction to close are also approval by the GLG Board of Directors and Nasdaq of the listing of the shares issued to execute he transaction.

    How will the acquisitions be handled by GLG?

    Providing the transactions complete successfully, the GLG chain of global operations will support lightweight new materials, applications and lightweight trucks. As a result of leveraging Jinmeike’s expertise in unmanned logistics as well as Jinbochuang’s knowledge of the new energy vehicle industry, TD Holdings (GLG) will be able to maximize its business and operational effectiveness.

  • DiDi Global Inc. (DIDI) Stock Continues Downward Spiral as Chinese Government Continues Crackdown on Tech Space

    DiDi Global Inc. (DIDI) Stock Continues Downward Spiral as Chinese Government Continues Crackdown on Tech Space

    DiDi Global Inc. (DIDI) stock prices were down 2.06% as of the market closing on July 15th, 2021, bringing the price per share down to USD$12.36 at the end of the trading day. Subsequent premarket fluctuations have seen the stock fall 6.96%, bringing it down to USD$11.50.

    CAC Investigation

    July 16th 2021 saw the Cyberspace Administration of China (CAC) report that officials from at least seven departments initiated the conducting of a cybersecurity review of DIDI, having sent officials on July 16th, 2021. The regulatory officials included the CAC, Ministry of Public Security, Ministry of State Security, Ministry of Transport, Ministry of Natural Resources, State Taxation Administration, and State Administration for Market Regulation.

    Government Involvement

    With the CAC not offering many details in its statement, the involvement of the myriad of government agencies signals the heavier regulatory pressure on the company, which will celebrate a decade of being in business in the upcoming year. The Chinese government is in the process of revamping its policies in regard to the privacy and data security. This includes the drafting of a Personal Information Protection Law, which will see tech platforms being required to impose stricter measures to ensure secure storage of user data.

    New Legislation

    September 2021 will see China implement its new Data Security Law, which will require companies that process “critical data” to conduct risk assessments and submit reports. The regulations will also call on organizations that process data affecting the country’s national security to submit annual reviews. The company currently has a market cap of around USD$60 billion and is reported to store all of its Chinese user and road data in China.

    DIDI IPO

    The Cyberspace Administration of China launched the data-related cybersecurity investigation into the company two days after its IPO. The New York initial public offering saw the company generate USD$4.4 billion in the capital. Furthermore, the company was ordered by the regulators to remove its application from the market space in China. This is expected to negatively affect the company’s revenue, despite the app continuing to be used by users who already had it downloaded.

    Future Outlook for DIDI

    With the Chinese government cracking down on companies like DIDI, shareholders are concerned about the future prospects of the commercial potential of their investments. The company is keen to comply with the newly announced regulations in a bid to consolidate its market footprint and mitigate the losses expected.

  • On What Basis Did MRNA Stock Rise 8% Premarket?

    On What Basis Did MRNA Stock Rise 8% Premarket?

    Shares of biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines Moderna Inc. (MRNA) were trading up 8.08% in the premarket session at $280.65 as of the last check. During the last trading session, Moderna stock closed at $ 259.67, up 5.28% or $ 13.01. In the course of the session, MRNA shares fluctuated between $245.505 and $261.22.

    During the day, 14.19 million shares of MRNA stock were traded, which is higher than the company’s 50-day daily volume of 8.75 million and higher than its year-to-date volume of 10.63 million. MRNA stock has retreated 223.70% over the past 12 months, and it has gained 11.55% over the last week. A total of 109.31% has been gained by MRNA stock during the last six months, while a total of 62.43% has been gained during the last three months.

    Currently, MRNA has returned 148.56 percent so far this year. The price to earnings ratio for the MRNA stock is 207.1 8. MRNA stock continued to rise as news had emerged that it has been added to S&P 500 and that quarterly earnings will be released soon.

    When will MRNA be added to the S&P 500?

    From a science research-stage company developing messenger RNA (mRNA) in the field of science over the past decade, Moderna has grown into an organization with a diverse clinical portfolio of vaccines and therapeutics in six different therapeutic areas. In addition to increasing the mRNA patent portfolio and launching a fully integrated manufacturing facility that would enable the Company to produce products both at scale and at unprecedented speed, MRNA has also expanded its intellectual property portfolio in the fields of lipid nanoparticle formulation and mRNA formulation.

    In addition to its alliances with domestic and overseas partners, MRNA maintains partnerships with many Canadian and international organizations. This has allowed MRNA to pursue revolutionary science as well as rapid scale-up. Recent developments at MRNA have enabled their capabilities to result in an authorized use of a vaccine that was among the earliest and most effective against the COVID-19 pandemic.

    Moderna will replace Alexion Pharmaceuticals Inc. on S&P 500 index, announced the company yesterday. MRNA will be included in the index prior to the opening of trading on Wednesday, July 21. Due to the acquisition of Alexion Pharmaceuticals by AstraZeneca Plc, MRNA has replaced Alexion on the charts pending final closing conditions.

    MRNA to release quarterly results:

    A live conference call and webcast will be held by Moderna on Thursday, August 5, 2021, at 8:00 am ET. MRNA will provide its corporate update and financial results ahead of the conference call.

    In addition to the live conference call, a webcast of the call will also be available in the Investors section of the Moderna (MRNA) website under “Events and Presentations.” MRNA will make the archived webcast available on its website shortly after the conference call ends, and will remain accessible for one year following the call.

  • Takung Art Co. Ltd. (TKAT) stock surged in the premarket trading session; find out why

    The Takung Art Co. Ltd. (TKAT stock) shares had surged in the premarket trading session in which the percentage boosted by 7.58% to trade at an increased price of $8.09 at last check. The previous session of the TKAT stock had closed gaining 8.67% at $7.52. The stock volume for an average daily within the past 50 days has been 1.94 million shares while today’s trade remained 33.64 million shares, which is higher. In the past year up to date, TKAT shares had surged up by 557.57% and in the past week, the stocks had dropped down by -36.59%. In the past three and six months, the TKAT stock had shed -65.94% and added 246.54% respectively. Furthermore, Takung Art Co. is currently valued in the market at $102.05 million and has 11.27 million outstanding shares.

    What you need to know about Takung Art Co. Ltd.

    Takung Art Co. Ltd. is an internet retail company that focuses on the buying and selling of art products online. The TKAT stock has an operational platform which is specifically an electronic online platform for artists, art investors, and dealers. Talung also trades in valuable pieces of artwork. The target market for the consumers and operations is in the People’s Republic of China. The name of the platform is www.takungae.com. This website consists of online listing and services of trade for all sorts of art and aesthetic consumers where they get access to art trading market. This allows for them to interact with investors that can invest in their art assets. These art assets include calligraphy, paintings, crafts, jade, jewelry, ceramics, metalware, antique furniture, and sculptures. The company has a client base consisting of original owners, agents, and traders. TKAT stock was founded in 2012 and is based in TsimShaTsui, Hong Kong.

    Takung has announced the closing of a $5.0 million private placement

    Takung Art Co. Ltd. has recently announced that it has closed up a private placement of the common stock that totals to a share number of 571,429. The purchase price listed for this TKAT common stock is $8.75 per share. The company has estimated the gross proceeds from this closing to be $5 million prior to excluding placement agent fees and expenses related to the offering. The general purposes for the use of these net proceeds from the offering are intended for corporate purposes and practices, and working capital expenditure. The sole manager for this placement is Maxim Group LLC.

    This $5.0 million private placement made by the operators of three online fine arts and collectibles platform was initiated on 8th of July and were conditioned to a securities purchase agreement (SPA) under the satisfaction of which, it will be closed.

  • What Is Driving The AEHR Stock Up 22% Premarket?

    At last check, shares of worldwide supplier of semiconductor test and reliability qualification equipment, Aehr Test Systems (AEHR) were trading for $3.44, up 22.42% in premarket session today. As of Thursday’s close, AEHR stock was down -0.71% at $2.81. Over the past 50 days, volumes of AEHR stock were 1.68 million shares, which was higher than the 0.5 million share traded on the day.

    Within the past week, AEHR shares have gained 18.57%, and were up 36.07 percent over the last 12 months. AEHR stock has gained 30.09% in the recent three months, while losing 24.89% in the recent six months. AEHR is currently valued at 57.75 million dollars; its outstanding shares are 23.52 million. AEHR stock rose after its quarterly results were released with encouraging revenue results.

    Is there something unique about AEHR?

    Aehr Test Systems, based in Fremont, California, manufactures and sells test systems that are used to burn-in and test logic, optical and memory integrated circuits. Aehr Test Systems has provided over 2,500 systems worldwide.

    Automobile and mobility markets’ quality and reliability requirements are driving more test requirements, increased testing needs, and new opportunities for AEHR products at the package, wafer, and module levels. AEHR has developed numerous innovative products, including the ABTS and FOX-P families of test and burn-in systems and the FOX DiePak Carrier, FOX DiePak Loader and FOX WaferPak Aligner.

    Aehr Test yesterday reported its fourth quarter and fiscal 2021 full year results ended May 31, 2021.

    Quarterly financial results:

    • AEHR’s net sales reached $7.6 million in the reported quarter, up 102% over the corresponding quarter last year.
    • Compared with a GAAP net loss of $2.9 million, or $0.13 per diluted share in Q4 2020, the net income posted by AEHR in Q4 2021 is $567,000, or $0.02 per diluted share.
    • Non-GAAP net income posted AEHR was $870,000, or $0.04 per diluted share, excluding stock-based compensation. The previous year’s non-GAAP net loss was $720,000, or $0.03 per diluted share.
    • The quarter’s bookings were $5.5 million, 113% more than the previous year quarter.
    • By May 31, 2021, there were $1.6 million in backlog.
    • Fiscal Year Financial Results:
    • In fiscal 2020, net sales posted by AEHR were $22.3 million, while in fiscal 2021 they were $16.6 million.
    • Compared with a GAAP net loss of $2.8 million, or $0.12 per diluted share, AEHR had a GAAP net loss of $2.0 million, or $0.09 per diluted share.
    • An non-GAAP net loss of $3.3 million, or $0.14 per diluted share, was reported by AEHR in comparison to an non-GAAP net loss of $27,000, or $0.00 per diluted share.

    How AEHR sees it performance?

    This year’s fiscal fourth quarter marks a return to pre-pandemic revenue and operating profit levels for AEHR. It was encouraging to see AEHR’s customer demand increase during the third quarter following the production ramp delays and pushouts it experienced during the previous year. To date, AEHR has booked $5.4 million in bookings for fiscal 2022 and has an effective backlog of $7 million.

  • Why Did The AXDX Stock Rise Nearly 10% In Extended Trades?

    In after-hours trading on Thursday, Accelerate Diagnostics Inc. (AXDX) rose 10.69% at $7.25. During the last trading session, Accelerate Diagnostics stock lost -2.38% to finish at $6.55. During the day, AXDX was trading between $6.50 and $6.79. There were 0.15 million shares traded on AXDX stock, lower than its daily average of 0.21 million shares over 100 days.

    Over the last five days, shares of AXDX fell by -8.90%, while overall, they declined by -27.14% during the past month. As a consequence of the announcement of its conference call date to discuss quarterly results, AXDX stock gained traction.

    When will ACDX release its results?

    Dedicated to providing solutions to the global challenges of sepsis and antibiotic resistance, Accelerate Diagnostics is a leading in vitro diagnostics company. As part of AXDX’s Accelerate Pheno system and Accelerate PhenoTest BC kit, clinicians are able to determine the most appropriate antibiotic therapy for serious infections more quickly.

    In about 7 hours directly from a positive blood culture, AXDX’s FDA-cleared system and kit automate sample preparation steps to provide phenotypic susceptibility results for antibiotics. The AXDX solution provides results one to two days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage based on the patient’s infection.

    An Accelerate Diagnostics conference call will be held at 4:30pm Eastern Time on Thursday, August 5, 2021. AXDX will review the financial results for the second quarter of 2021.

    Investors can listen to the audio webcast online by visiting the AXDX website. AXDX will make the audio webcast replay available through November 5, 2021.

    Added to its Accelerate PhenoTest BC kit is a new IVD configuration launched by Accelerate Diagnostics recently in the United States.

    • AXDX is now offering two solutions for rapid sepsis testing.
    • A fast and flexible solution for laboratories who already have rapid identification systems, the new configuration provides fast antimicrobial susceptibility testing (AST) results from positive blood cultures in approximately 7 hours.
    • As a result, labs needing both fast identification and fast AST now have an integrated solution with AXDX’s FDA-cleared Accelerate PhenoTest BC kit, which includes an ID/AST configuration.
    • Rapid improvements in clinical outcomes have been demonstrated with the Accelerate Pheno system, including faster time to results, a shorter therapy duration, and a shorter hospital stay.

    How this expansion will benefit AXDX?

    Accelerate Diagnostics (AXDX)’s rapid susceptibility testing product expansion will give customers new access to our proven benefits. Generally, market feedback has been positive, especially from customers who already have rapid identification systems, but still need susceptibility results as soon as possible to support patients in getting the right treatment. AST configuration will drive sales funnels, Pheno placements, and future revenues for AXDX based on the strong interest from customers as well as improved access.